Other
Finite-Lived Intangible Assets, Accumulated Amortization
Pfizer Finite-Lived Intangible Assets, Accumulated Amortization increased by 1.9% to $73.86B in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
A steady increase is expected as assets age; a sudden jump may indicate accelerated amortization or impairment charges.
Detailed definition
This is the cumulative amount of amortization expense recognized against finite-lived intangible assets over their usefu...
Peer comparison
Standard accounting practice for tracking the consumption of intangible assets.
Metric ID:
other_finite_lived_intangible_assets_accumulated_amortizationHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $72.50B | $73.86B |
| QoQ Change | — | +1.9% |
Range$72.50B – $73.86B
Finite-Lived Intangible Assets, Accumulated Amortization at Other Companies
Frequently Asked Questions
- What is Pfizer's finite-lived intangible assets, accumulated amortization?
- Pfizer (PFE) reported finite-lived intangible assets, accumulated amortization of $73.86B in Q1 2026.
- What does finite-lived intangible assets, accumulated amortization mean?
- The total value of intangible assets already written off over time.